TrialMolecular oncology2014

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Filippo Montemurro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.